vs
Side-by-side financial comparison of Civeo Corp (CVEO) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $161.6M, roughly 1.1× Civeo Corp). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs -4.0%, a 4.9% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 7.1%). AMICUS THERAPEUTICS, INC. produced more free cash flow last quarter ($16.0M vs $14.5M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs -1.4%).
The Civeo Corporation is an American accommodation services multinational corporation. It is a spin-off of Oil States International. It is a public company listed on the New York Stock Exchange.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
CVEO vs FOLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $161.6M | $185.2M |
| Net Profit | $-6.5M | $1.7M |
| Gross Margin | 22.7% | 85.7% |
| Operating Margin | -0.1% | 8.6% |
| Net Margin | -4.0% | 0.9% |
| Revenue YoY | 7.1% | 23.7% |
| Net Profit YoY | 58.1% | -88.5% |
| EPS (diluted) | $-0.58 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $161.6M | $185.2M | ||
| Q3 25 | $170.5M | $169.1M | ||
| Q2 25 | $162.7M | $154.7M | ||
| Q1 25 | $144.0M | $125.2M | ||
| Q4 24 | $151.0M | $149.7M | ||
| Q3 24 | $176.3M | $141.5M | ||
| Q2 24 | $188.7M | $126.7M | ||
| Q1 24 | $166.1M | $110.4M |
| Q4 25 | $-6.5M | $1.7M | ||
| Q3 25 | $-455.0K | $17.3M | ||
| Q2 25 | $-3.3M | $-24.4M | ||
| Q1 25 | $-9.8M | $-21.7M | ||
| Q4 24 | $-15.4M | $14.7M | ||
| Q3 24 | $-5.1M | $-6.7M | ||
| Q2 24 | $8.2M | $-15.7M | ||
| Q1 24 | $-5.1M | $-48.4M |
| Q4 25 | 22.7% | 85.7% | ||
| Q3 25 | 25.7% | 88.5% | ||
| Q2 25 | 25.3% | 90.2% | ||
| Q1 25 | 20.4% | 90.7% | ||
| Q4 24 | 18.6% | 90.1% | ||
| Q3 24 | 21.4% | 90.6% | ||
| Q2 24 | 25.4% | 91.1% | ||
| Q1 24 | 21.5% | 87.7% |
| Q4 25 | -0.1% | 8.6% | ||
| Q3 25 | 4.1% | 20.3% | ||
| Q2 25 | 1.7% | -6.1% | ||
| Q1 25 | -3.8% | -6.3% | ||
| Q4 24 | -6.7% | 10.7% | ||
| Q3 24 | 0.0% | 15.3% | ||
| Q2 24 | 6.9% | 11.8% | ||
| Q1 24 | -1.1% | -25.1% |
| Q4 25 | -4.0% | 0.9% | ||
| Q3 25 | -0.3% | 10.2% | ||
| Q2 25 | -2.0% | -15.8% | ||
| Q1 25 | -6.8% | -17.3% | ||
| Q4 24 | -10.2% | 9.8% | ||
| Q3 24 | -2.9% | -4.8% | ||
| Q2 24 | 4.4% | -12.4% | ||
| Q1 24 | -3.1% | -43.9% |
| Q4 25 | $-0.58 | $0.00 | ||
| Q3 25 | $-0.04 | $0.06 | ||
| Q2 25 | $-0.25 | $-0.08 | ||
| Q1 25 | $-0.72 | $-0.07 | ||
| Q4 24 | $-1.04 | $0.05 | ||
| Q3 24 | $-0.36 | $-0.02 | ||
| Q2 24 | $0.56 | $-0.05 | ||
| Q1 24 | $-0.35 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.4M | $293.5M |
| Total DebtLower is stronger | — | $392.7M |
| Stockholders' EquityBook value | $174.4M | $274.2M |
| Total Assets | $477.4M | $949.9M |
| Debt / EquityLower = less leverage | — | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $293.5M | ||
| Q3 25 | $12.0M | $263.8M | ||
| Q2 25 | $14.6M | $231.0M | ||
| Q1 25 | $28.4M | $250.6M | ||
| Q4 24 | $5.2M | $249.9M | ||
| Q3 24 | $17.9M | $249.8M | ||
| Q2 24 | $7.4M | $260.1M | ||
| Q1 24 | $16.8M | $239.6M |
| Q4 25 | — | $392.7M | ||
| Q3 25 | — | $392.0M | ||
| Q2 25 | — | $391.3M | ||
| Q1 25 | — | $390.7M | ||
| Q4 24 | $43.3M | $390.1M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $388.9M | ||
| Q1 24 | — | $388.4M |
| Q4 25 | $174.4M | $274.2M | ||
| Q3 25 | $182.5M | $230.4M | ||
| Q2 25 | $209.4M | $204.3M | ||
| Q1 25 | $220.7M | $193.6M | ||
| Q4 24 | $236.4M | $194.0M | ||
| Q3 24 | $282.2M | $178.8M | ||
| Q2 24 | $297.4M | $132.5M | ||
| Q1 24 | $297.4M | $130.7M |
| Q4 25 | $477.4M | $949.9M | ||
| Q3 25 | $491.1M | $868.8M | ||
| Q2 25 | $508.8M | $815.3M | ||
| Q1 25 | $423.8M | $789.8M | ||
| Q4 24 | $405.1M | $785.0M | ||
| Q3 24 | $477.6M | $786.6M | ||
| Q2 24 | $483.2M | $749.5M | ||
| Q1 24 | $513.1M | $721.8M |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | 0.18× | 2.01× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.93× | ||
| Q1 24 | — | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.3M | $16.3M |
| Free Cash FlowOCF − Capex | $14.5M | $16.0M |
| FCF MarginFCF / Revenue | 8.9% | 8.6% |
| Capex IntensityCapex / Revenue | 3.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.3M | $16.3M | ||
| Q3 25 | $13.8M | $35.7M | ||
| Q2 25 | $-2.3M | $-26.5M | ||
| Q1 25 | $-8.4M | $7.8M | ||
| Q4 24 | $9.5M | $-3.9M | ||
| Q3 24 | $35.7M | $-23.0M | ||
| Q2 24 | $32.4M | $22.7M | ||
| Q1 24 | $6.0M | $-29.7M |
| Q4 25 | $14.5M | $16.0M | ||
| Q3 25 | $8.2M | $35.3M | ||
| Q2 25 | $-6.8M | $-28.9M | ||
| Q1 25 | $-13.7M | $7.5M | ||
| Q4 24 | $1.8M | $-4.2M | ||
| Q3 24 | $28.2M | $-23.3M | ||
| Q2 24 | $27.0M | $21.6M | ||
| Q1 24 | $372.0K | $-31.5M |
| Q4 25 | 8.9% | 8.6% | ||
| Q3 25 | 4.8% | 20.9% | ||
| Q2 25 | -4.2% | -18.7% | ||
| Q1 25 | -9.5% | 6.0% | ||
| Q4 24 | 1.2% | -2.8% | ||
| Q3 24 | 16.0% | -16.5% | ||
| Q2 24 | 14.3% | 17.0% | ||
| Q1 24 | 0.2% | -28.5% |
| Q4 25 | 3.0% | 0.2% | ||
| Q3 25 | 3.3% | 0.2% | ||
| Q2 25 | 2.8% | 1.6% | ||
| Q1 25 | 3.7% | 0.2% | ||
| Q4 24 | 5.1% | 0.2% | ||
| Q3 24 | 4.2% | 0.3% | ||
| Q2 24 | 2.8% | 0.9% | ||
| Q1 24 | 3.4% | 1.6% |
| Q4 25 | — | 9.62× | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.93× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVEO
Segment breakdown not available.
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
